On May 9, 2025, Sirius Therapeutics announced the successful completion of a nearly US$50 million Series B2 financing round to accelerate the clinical development of its novel small interfering RNA (siRNA) therapies for cardiometabolic diseases and to further innovate its next-generation RNA delivery technology. This round of financing was led by a globally renowned industry investment institution, with participation from BioTrack Capital and existing investors Orbimed, Hongyuan Capital, and Hanscan Capital.

Read the original text

Full Range of Chromatography Equipment, Software, and Consumables Made in ChinaPlatform EnterpriseAcchrom Tech (Beijing) Co., Ltd.("Acchrom Tech" hereinafter)Completed Pre-B Round Financing of Over 100 Million Yuan，This round of financing was co-led by Jingguorui Fund and Beijing High-Precision Fund managed by BGIC, with follow-up investments from existing shareholders Hony Capital and Bridge Capital., The funds raised in this round will be mainly used for further construction of sales channels at home and abroad and the development of the next generation of products.。

Read the Original Text

Salus Medical Technology (Shenzhen) Co., Ltd. (hereinafter referred to as "Salus") announced the completion of its Series A+ financing. This round of financing was led by Fosun Pharma, a leading company in the healthcare industry, with Changzhou Weichi Investment participating, and existing shareholder Shenzhen Capital Group continuing to increase its investment.This round of funding will focus on the registration and application of China's national sequencing platform, capacity expansion, and the globalization of market expansion, further consolidating its leading position in innovation within the life science tools sector.

Read the Original Text

On May 16, 2025, CANbridge Pharmaceutical Inc. (hereinafter referred to as "CANbridge", stock code "01228.HK") announced that its wholly-owned subsidiary, CANbridge (Shanghai) Biotechnology Co., Ltd., obtained approval from the National Medical Products Administration for the listing of Velaglucerase Alfa for Injection (brand name: Gorenin).Gorining is the first domestically self-developed enzyme replacement therapy in China for long-term treatment of Type I and Type III Gaucher disease in patients aged 12 years and above, including both adolescents and adults. As an innovative Class 1 drug, it can fully replace similar imported products, significantly improving the accessibility of treatment for patients in China.

Read the Original Text

On May 29, it was learned from the NMPA website that Hycure Pharma (688302.SH) independently developed Class I new drug Haina An® (generic name: Deuterated Enzalutamide Soft Capsules), which has been approved for marketing by the National Medical Products Administration., for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have experienced disease progression after receiving abiraterone acetate and chemotherapy, and who have not previously received novel androgen receptor inhibitors.As a project supported by the National Science and Technology Major Project for Significant New Drug Development, deuterated enzalutamide soft capsules are the first domestically produced innovative drug approved for marketing in China to treat this indication.

Read the original text

Read the original text

Read the original text

On May 20, Sirius Therapeutics and CRISPR Therapeutics announced a strategic partnership to jointly advance the co-development and commercialization of siRNA therapies. This collaboration combines the complementary capabilities of both parties in research and development as well as industrialization, aiming to co-develop and commercialize SRSD107, a next-generation long-acting Factor XI (FXI) targeted small interfering RNA (siRNA) therapy, for the treatment of thrombotic and thromboembolic diseases.

According to the terms of the agreement, Sirius Therapeutics will receive $95 million in cash and cash equivalents as an upfront payment from CRISPR Therapeutics and is eligible to receive over $800 million in upfront and milestone payments. The two parties will jointly develop SRSD107 under a 50:50 cost and profit-sharing mechanism. Additionally, the agreement grants CRISPR Therapeutics the exclusive right of first negotiation to license up to two additional siRNA programs in the future.

Read the Original Text